Form 4 for PYXS Pyxis Oncology, Inc.

Accepted 2021-10-15 00:00:00 ET · period of report 2021-10-13 · accession 0001140361-21-034643 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-10-15	2021-10-13	PYXS	FLAVIN JOHN L	Dir	C - Cnv Deriv	—	+2,388	171.6K	+1%	—
D	2021-10-15	2021-10-13	PYXS	FLAVIN JOHN L	Dir	C - Cnv Deriv	$0.00	-15.2K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-13	C	A	2,388	—	171,610	D	—	—	(F1) These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. (F2) Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.
2	Derivative	Series B Convertible Preferred Stock	2021-10-13	C	D	15,190	$0.00	0	D	— · — to —	2,388 Common Stock	(F1) These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.